Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Silence Therapeutics (SLN) Return on Assets (2021 - 2025)

Historic Return on Assets for Silence Therapeutics (SLN) over the last 5 years, with Q3 2025 value amounting to 0.41%.

  • Silence Therapeutics' Return on Assets fell 3000.0% to 0.41% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.41%, marking a year-over-year decrease of 3000.0%. This contributed to the annual value of 0.28% for FY2024, which is 1400.0% up from last year.
  • Latest data reveals that Silence Therapeutics reported Return on Assets of 0.41% as of Q3 2025, which was down 3000.0% from 0.47% recorded in Q2 2025.
  • Over the past 5 years, Silence Therapeutics' Return on Assets peaked at 0.09% during Q2 2024, and registered a low of 0.47% during Q2 2025.
  • In the last 5 years, Silence Therapeutics' Return on Assets had a median value of 0.13% in 2023 and averaged 0.19%.
  • Its Return on Assets has fluctuated over the past 5 years, first skyrocketed by 1300bps in 2022, then tumbled by -3800bps in 2025.
  • Quarter analysis of 5 years shows Silence Therapeutics' Return on Assets stood at 0.24% in 2021, then soared by 51bps to 0.12% in 2022, then fell by -11bps to 0.13% in 2023, then grew by 21bps to 0.1% in 2024, then tumbled by -298bps to 0.41% in 2025.
  • Its last three reported values are 0.41% in Q3 2025, 0.47% for Q2 2025, and 0.4% during Q1 2025.